trending Market Intelligence /marketintelligence/en/news-insights/trending/stio__y67ig5q8x5pmt57g2 content esgSubNav
In This List

Aurinia Pharmaceuticals appoints director

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Aurinia Pharmaceuticals appoints director

Canada's Aurinia Pharmaceuticals Inc. added Michael Hayden to its board.

Hayden most recently served as president of global research and development and chief scientific officer at Teva Pharmaceutical Industries Ltd.